Chronic lymphocytic leukemia: Economic burden and quality of life: Literature review

American Journal of Therapeutics

Volumn 12, Issue 5, 2005, Pages 460-466

  Stephens, Jennifer M ^a   Gramegna, Paola ^b   Laskin, Benjamin ^a   Botteman, Marc F ^a   Pashos, Chris L ^c,d  

^a HERQuLES   (United States)

^b Pharmacia Corporation   (Italy)

^c HERQuLES   (United States)

^d ABT ASSOCIATES   (United States)

Author keywords

Chronic lymphocytic leukemia; Cost identification; Cost of illness; Cost effectiveness; Economic burden; Quality of life

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; HEMOGLOBIN; IMMUNOGLOBULIN G; PENTOSTATIN; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; VINCRISTINE;

ANEMIA; BONE MARROW TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CYTOTOXICITY TEST; DEATH; DISABILITY; ECONOMIC ASPECT; EMPLOYMENT; FATIGUE; FEAR; HEALTH CARE COST; HEALTH INSURANCE; HEMOGLOBIN DETERMINATION; HUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH EXPENDITURES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; QUALITY OF LIFE; STEM CELL TRANSPLANTATION;

EID: 26844510714     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000104489.93653.0f     Document Type: Review

References (26)

1. Cheson BD. Chronic Lymphocytic Leukemias. In: Abeloff MD, Armitage JO, Lichter AS, et al, eds. Clinical oncology. New York: Churchill Livingstone; 2000:2536-2563.
2. Kipps TJ. Chronic lymphocytic leukemia and related diseases. In: Beutler E, Coller BS, Lichtman MA, et al, eds. Williams hematology. New York: McGraw-Hill; 2001:1163-1194.
3. Andritsos L, Khoury H. Chronic lymphocytic leukemia. Curr Treat Options Oncol. 2002;3:225-231.
4. Diehl LF, Karnell LH, Menck HR. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer. 1999;86:2684-2692.
5. Wendtner CM, Schmitt B, Bergmann M, et al. New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia. Int J Hematol. 2001;73:32-38.
6. Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-2494.
7. Siakantaris MP, Angelopoulou MK, Vassilakopoulos TP, et al. Correction of disease related anaemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin: maintenance is necessary to sustain response. Leuk Lymphoma. 2000;40:141-147.
8. Haber J, Spicka I, Petruzelka L, et al. Recombinant human erythropoietin in the treatment of anemia associated with lymphoproliferative diseases-chronic lymphadenosis and multiple myeloma. Vnitr Lek. 1996;42:262-267.
9. Hays K, McCartney S. Nursing care of the patient with chronic lymphocytic leukemia. Semin Oncol. 1998;25: 75-79.
10. Cella D. Functional Assessment of Cancer Therapy website. www.facit.org, accessed June 2002.
11. Hyde C, Wake B, Bryan S, et al. Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment. Health Technol Assess. 2002;6: 1-89.
12. Holzner B, Kemmler G, Sperner-Unterweger B, et al. Quality of life measurement in oncology-a matter of the assessment instrument? Eur J Cancer. 2001;37:2349-2356.
13. Levy V, Porcher R, Delabarre F, et al. Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis. J Clin Epidemiol. 2001;54:747-754.
14. Bertero C, Eriksson BE, Ek AC. A substantive theory of quality of life of adults with chronic leukaemia. Int J Nurs Stud. 1997;34:9-16.
15. Mason JM, Drummond MF, Bosanquet AG, Sheldon TA. The DiSC assay. A cost-effective guide to treatment for chronic lymphocytic leukemia? Int J Technol Assess H Care. 1999;15:173-184.
16. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med. 1991;325:81-86.
17. Agency for Healthcare Research and Quality (AHRQ). HCUPnet, Health Care Utilization Project. 2002.
18. Baltz JK, Montello MJ. Cladribine for the treatment of hematologic malignancies. Clin Pharm. 1993;12:805-813.
19. Marchetti M, Barosi G, Liberato LN. Fludarabine for chronic lymphocytic leukemia. N Engl J Med. 2001;344: 1166-1167.
20. Bosanquet AG, Johnson SA, Richards SM. Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. Br J Haematol. 1999;106:71-77.
21. Hamblin TJ. Achieving optimal outcomes in chronic lymphocytic leukaemia. Drugs. 2001;61:593-611.
22. Alemtuzumab. Am J Health Syst Pharm. 2001;58:2372-2373.
23. Ballow M. Intravenous immunoglobulins: clinical experience and viral safety. J Am Pharm Assoc (Wash). 2002;42: 449-458.
24. Timmerman PR. Intravenous immunoglobulin in oncology nursing practice. Oncol Nurs Forum. 1993;20:69-75.
25. Bennett C, Waters T, Stinson T, et al. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;24:555-560.
26. Venuta F, Rendina EA, Pescarmona EO, et al. Ambulatory mediastinal biopsy for hematologic malignancies. Eur J Cardiothorac Surg. 1997;11:218-221.